Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA09 Oct 2025, 21:49 UTC
AI-generated source summary
The analysis evaluates UnitedHealth (UNH) using forward price-to-earnings ratios from Fiscal AI and a proprietary discounted cash flow model. It notes UNH's forward P/E of 22 and increase from lows of 14-13 earlier in the year. The DCF model suggests an intrinsic value of $449.17 per share, compared to a current market price of $358.77. The analyst believes the company undervalued, taking into account consistent free cash flow and customer base. The underperformance in 2025 is attributed to a company's misjudgment in estimates for how much it will cost to serve their customers, something correctable by adjusting the pricing policy. The last evaluation, on September 23rd, rated UNH as a buy, risk/reward remain attractive. The analyst acknowledges a business trading at a lower price will provide better opportunity, noting when it was trading at 275/250 or even 285. The analyst considers this a buy, rating to be confirmed.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.